Journal
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY
Volume 43, Issue 2, Pages 290-293Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.jcms.2014.11.014
Keywords
Bisphosphonate; Denosumab; Osteonecrosis of the jaw; BRONJ; Surgical treatment; Fluorescence-guided bone resection
Categories
Ask authors/readers for more resources
The medication-related osteonecrosis of the jaw (MRONJ) is believed to be a therapy-resistant entity. Although the application of the recommended conservative and surgical treatment regimens have returned variable success rates, the increased awareness and experience with MRONJ suggests that surgical therapy can halt the progression of the disease, thereby allowing a histology-based diagnosis of the osteonecrosis. Surgical treatment protocols can achieve success rates of over 90% and novel techniques such as the visualization of bone fluorescence can assist in the intra-operative delineation of the osteonecrosis and standardize the procedure. (C) 2014 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available